Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright raised their price target on the stock from $70.00 to $100.00.

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) had its price target upped by stock analysts at Laidlaw from $75.00 to $105.00 in a research note issued to investors on Thursday, ...

Access Soleno Therapeutics stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.